TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25140039

Group type: EXPERIMENTAL
Intervention: Afatinib (A) 40 mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Afatinib plus Temozolomide (AT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Temozolomide (T) 75 mg/m2 for 21 of 28 days
Number of subjects: 119
Study: 24024757

Group type: EXPERIMENTAL
Intervention: Sodium alginate suspension 20 mL three times a day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 195
Study: 21619980

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CPB)
Number of subjects: 200
Study: 19386025

Group type: EXPERIMENTAL
Intervention: TIPS-LBPV
Number of subjects: 72

Group type: COMPARATOR
Intervention: TIPS-RBPV
Number of subjects: 72
Study: 16762764

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) in patients with Takayasu's arteritis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects without aortic disease defined by TEE
Number of subjects: 14
Study: 15328899

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg titrated to 5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11086300

Group type: EXPERIMENTAL
Intervention: Single dose of 2 lakh units of Vitamin A orally (experimental group)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No Vitamin A supplementation (control group)
Number of subjects: 109
Study: 9545677

Group type: EXPERIMENTAL
Intervention: High intensity strength training (EXH: 2 sets of 8 to 10 repetitions for 75 to 85% of 1 RM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low intensity strength training (EXL: 2 sets of 14 to 16 repetitions for 55 to 65% of 1 RM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 42
Study: 8164614

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 3296295

Group type: EXPERIMENTAL
Intervention: Treatment A (breathing exercises emphasizing inspiration with forced expiration technique in gravity assisted positions)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treatment B (breathing exercises with positive expiratory pressure alternating with forced expiration technique in gravity assisted positions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment C (breathing exercises with positive expiratory pressure and forced expiration technique in sitting position)
Number of subjects: 18
Study: 30311825

Group type: EXPERIMENTAL
Intervention: α-Lipoic Acid (7 mg/kg), Carnosine (6 mg/kg), Thiamine (1 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 27561937

Group type: EXPERIMENTAL
Intervention: VBAC (TOLAC)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: VBAC
Number of subjects: 507

Group type: COMPARATOR
Intervention: ERCS
Number of subjects: 507
Study: 25123219

Group type: EXPERIMENTAL
Intervention: 7-day-week therapy
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 283

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 283
Study: 23249479

Group type: EXPERIMENTAL
Intervention: Web-based course on management of atopic dermatitis with email/MMS guidance; Duration: 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: No education or guidance (control group)
Number of subjects: 46
Study: 19934443

Group type: EXPERIMENTAL
Intervention: EXDASE program (3-month duration)
Number of subjects: 52
Study: 18522057

Group type: EXPERIMENTAL
Intervention: R package for single-case randomization tests
Number of subjects: 0
Study: 15516351

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% plus 0.150 mg of clonidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus 0.150 mg of clonidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Number of subjects: 80
Study: 12806381

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (6-monthly injections)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Goserelin acetate (6-monthly injections)
Number of subjects: 50
Study: 10368835

Group type: EXPERIMENTAL
Intervention: Maximal lateral pinch grip efforts in individuals with myotonic dystrophy
Number of subjects: 18
Study: 8677864

Group type: EXPERIMENTAL
Intervention: Ambulatory electrocardiographic (AECG) monitoring
Number of subjects: 1820
Study: 2053506

Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg daily) - simplified three-step regimen
Number of subjects: 173

Group type: COMPARATOR
Intervention: Bromocriptine (15 mg daily) - standard seven-step regimen
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg daily) - both regimens
Number of subjects: 173
Study: 6336981

Group type: EXPERIMENTAL
Intervention: CMF plus T (cyclophosphamide, methotrexate, 5-fluorouracil plus tamoxifen)
Number of subjects: 145

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: CMF plus T
Number of subjects: 145

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Second-line CMF plus T
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Treatment A (CMF)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Treatment B (CMF plus T)
Number of subjects: 145
Study: 30958066

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/BM)
Number of subjects: 15
Study: 29956572

Group type: EXPERIMENTAL
Intervention: Educational outreach visits by pharmacists (academic detailing)
Number of subjects: 307
Study: 26993976

Group type: EXPERIMENTAL
Intervention: WATCHMAN device
Number of subjects: 485
Study: 25005467

Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg) plus methotrexate (MTX)
Number of subjects: 219
Study: 21816029

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine with booster dose of RTS,S/AS01
Number of subjects: 6000

Group type: COMPARATOR
Intervention: RTS,S/AS01 vaccine with control vaccine at time of booster
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control vaccine at time of primary vaccination and booster
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 6000
Study: 19947263

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medicine group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 92
Study: 17713976

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vildagliptin 25mg intravenous infusion
Number of subjects: 11
Study: 15733479

Group type: EXPERIMENTAL
Intervention: Nimodipine infusion (20 microg.kg(‐1).h(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane anesthesia (1 MAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nimodipine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 30
Study: 11999816

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (CA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (TA)
Number of subjects: 68
Study: 9550505

Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD) with 10% hydroxyethyl starch 200/0.5 (HES) over 5 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (pure rehydration with Ringer's lactate)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7886396

Group type: EXPERIMENTAL
Intervention: L-tryptophan (50 mM, pH 5.7)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: D-tryptophan (50 mM, pH 5.7)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: L-tryptophan and D-tryptophan (50 mM, pH 5.7)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal saline (pH 5.5)
Number of subjects: 11
Study: 2896402

Group type: EXPERIMENTAL
Intervention: 30 mg acetylsalicylic acid
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicylic acid
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 29464680

Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Transurethral Incision of the Prostate (TUIP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (TURP vs TUIP)
Number of subjects: 79
Study: 27058906

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (4,000 IU [100 μg] daily)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Matching non-calcium-based placebo
Number of subjects: 229
Study: 25027749

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 3 gr every 6 hours for 72 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group received all standard ICU therapies
Number of subjects: 44
Study: 23022759

Group type: EXPERIMENTAL
Intervention: LMWH-nadroparin calcium (0.3 or 0.4 mL sc) administered 2 hours before surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium administered daily post-surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received LMWH-nadroparin calcium 8 hours after surgery
Number of subjects: 100
Study: 20223782

Group type: EXPERIMENTAL
Intervention: Hierarchical Bayes model for surgical procedure choice
Number of subjects: 0
Study: 18614928

Group type: EXPERIMENTAL
Intervention: Microbicide active against curable STIs
Number of subjects: 0
Study: 16095253

Group type: EXPERIMENTAL
Intervention: Home visits by research assistants from the local community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12585970

Group type: EXPERIMENTAL
Intervention: Full dose regimen of cotrimoxazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Escalating dose regimen of cotrimoxazole starting with 75 mg/day, doubled every 48 hours
Number of subjects: 18
Study: 10717551

Group type: EXPERIMENTAL
Intervention: Multidimensional movement analysis system
Number of subjects: 81
Study: 9053970

Group type: EXPERIMENTAL
Intervention: Polysucrose 15000 (PS 15000)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 51Cr-labelled ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 14C-mannitol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 20
Study: 2149912

Group type: EXPERIMENTAL
Intervention: 30 micrograms Ethinylestradiol (EE) and 150 micrograms Desogestrel (DG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 75 micrograms Gestodene (GD)
Number of subjects: 34
Study: 7018361

Group type: EXPERIMENTAL
Intervention: Amiloride/Hydrochlorothiazide (A/HCTH) combination
Number of subjects: 43

Group type: COMPARATOR
Intervention: Furosemide plus potassium supplementation (FUR/P)
Number of subjects: 43
Study: 31603582

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (Battlefield protocol)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control (bandages alone)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 134
Study: 30392736

Group type: EXPERIMENTAL
Intervention: Rapid test group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control standard-of-care group
Number of subjects: 254
Study: 28089680

Group type: EXPERIMENTAL
Intervention: AREDS2 participants with AMD
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control subjects without AMD
Number of subjects: 484
Study: 25575067

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: leflunomide (LEF)
Number of subjects: 100
Study: 24041733

Group type: EXPERIMENTAL
Intervention: Four sessions of birth and parent preparation in small groups
Number of subjects: 2350

Group type: COMPARATOR
Intervention: Two lectures in an auditorium
Number of subjects: 2350
Study: 22028163

Group type: EXPERIMENTAL
Intervention: Music therapy for four weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 18
Study: 18953549

Group type: EXPERIMENTAL
Intervention: Seprafilm (sodium hyaluronate-based bioresorbable membrane)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group (no Seprafilm)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 427
Study: 16215804

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12183857

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study: 10480500

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 14
Study: 8763180

Group type: EXPERIMENTAL
Intervention: Bifurcation advancement closure
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patch angioplasty
Number of subjects: 25

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bifurcation advancement
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patch closure
Number of subjects: 25
Study: 2009893

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7064673

Group type: EXPERIMENTAL
Intervention: Modified Bandi procedure (anterior displacement of the tibial tuberosity)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard shaving procedure
Number of subjects: 42
Study: 31488156

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 157
Study: 28327693

Group type: EXPERIMENTAL
Intervention: Single visit treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Two visits with 1-week intracanal calcium hydroxide medication
Number of subjects: 199
Study: 26499256

Group type: EXPERIMENTAL
Intervention: PACT model (intervention group)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1200
Study: 23708174

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8782

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg and Placebo
Number of subjects: 8782
Study: 21513721

Group type: EXPERIMENTAL
Intervention: Chronic i.c.v. application of ghrelin in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single s.c. injection of ghrelin under cold exposure in mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four-hour intravenous ghrelin infusion in healthy humans
Number of subjects: 0
Study: 19948089

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 17429911

Group type: EXPERIMENTAL
Intervention: 30% glucose
Number of subjects: 110

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 110
Study: 16491678

Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Red dim light placebo condition (200 lux)
Number of subjects: 31
Study: 12021712

Group type: EXPERIMENTAL
Intervention: Endovenous obliteration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional stripping operation
Number of subjects: 28
Study: 10619348

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg po QID for 6 weeks
Number of subjects: 6
Study: 7553992

Group type: EXPERIMENTAL
Intervention: Humidifier group (n = 10) using humidified and warmed gases at 40 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oesophageal group (n = 10) using an oesophageal heat exchanger
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 10) with no active warming
Number of subjects: 30
Study: 1933205

Group type: EXPERIMENTAL
Intervention: 111In‐labelled P256 Fab' imaging
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intra‐arterial thrombolysis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Negative scans
Number of subjects: 17

Group type: COMPARATOR
Intervention: Arteriographic appearances
Number of subjects: 17
Study: 6804164

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (30 micrograms/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Copper-releasing IUD (Nova-T)
Number of subjects: 110
Study: 29558784

Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg/daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gliclazide extended‐release (30 mg/daily for HbA1c 7.5‐8.0% and 60 mg/daily for HbA1c 8.0‐8.5%)
Number of subjects: 80
Study: 30091945

Group type: COMPARATOR
Intervention: VAC (Vincristine, Dactinomycin, and Cyclophosphamide)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: VAC/VI (Vincristine and Irinotecan)
Number of subjects: 448
Study: 27555196

Group type: EXPERIMENTAL
Intervention: Active prewarming with a Mistral‐Air warming system initially set to 43°C
Number of subjects: 115

Group type: COMPARATOR
Intervention: No active prewarming
Number of subjects: 115
Study: 24169460

Group type: EXPERIMENTAL
Intervention: Age at adiposity rebound (AR)
Number of subjects: 2880

Group type: EXPERIMENTAL
Intervention: Peak weight velocity (PWV)
Number of subjects: 2880

Group type: EXPERIMENTAL
Intervention: BMI at age at adiposity rebound (AR)
Number of subjects: 2880

Group type: EXPERIMENTAL
Intervention: Peak height velocity (PHV)
Number of subjects: 2880
Study: 22882750

Group type: EXPERIMENTAL
Intervention: Everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-exposure tacrolimus (TAC Control)
Number of subjects: 0
Study: 20972845

Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg twice daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 220
Study: 17687150

Group type: EXPERIMENTAL
Intervention: Statin use (n=6 RCTs)
Number of subjects: 1500000

Group type: EXPERIMENTAL
Intervention: Statin use (n=3 cohort studies)
Number of subjects: 1500000

Group type: EXPERIMENTAL
Intervention: Statin use (n=9 case-control studies)
Number of subjects: 1500000
Study: 15875108

Group type: EXPERIMENTAL
Intervention: High right atrial pacing (HRA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Dual site right atrial pacing (DAP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard pacing (SP)
Number of subjects: 79
Study: 11952485

Group type: EXPERIMENTAL
Intervention: Dorzolamide TID for 6 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo TID for 6 weeks
Number of subjects: 47
Study: 9796227

Group type: EXPERIMENTAL
Intervention: Depressed-mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schema induction organized around the theme of writing a paper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arousal induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control neutral-mood induction
Number of subjects: 0
Study: 8684925

Group type: EXPERIMENTAL
Intervention: Random Variability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Blocked Variability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Specific
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study: 1710741

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 338253

Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.05% betamethasone 17,21-dipropionate cream
Number of subjects: 40
Study: 31586310

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 92
Study: 29473173

Group type: EXPERIMENTAL
Intervention: Pathogen-reduction treatment (using Mirasol or Intercept systems)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Conventional platelets
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Intercept-treated patients
Number of subjects: 358

Group type: COMPARATOR
Intervention: Mirasol study patients
Number of subjects: 358
Study: 26215702

Group type: EXPERIMENTAL
Intervention: Variolink N high viscosity cement
Number of subjects: 50

Group type: COMPARATOR
Intervention: G‐Cem Automix cement
Number of subjects: 50

Group type: COMPARATOR
Intervention: G‐Cem Automix cement at 37°C
Number of subjects: 50
Study: 24874564

Group type: EXPERIMENTAL
Intervention: Wholegrain rye kernel bread (RKB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Boiled rye kernels (RK)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In vitro fermentation of RKB and RK
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In vitro fermentation of RKB
Number of subjects: 12
Study: 22172907

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IFRT) 30 Gy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no IFRT)
Number of subjects: 124
Study: 20127909

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Negative affectivity and current depression
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Change of cognitive performance
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Neuropsychological compromise
Number of subjects: 101
Study: 18763255

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cryostripping
Number of subjects: 120
Study: 15785912

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 18
Study: 12849773

Group type: EXPERIMENTAL
Intervention: Executive tasks administered to children with Klinefelter's syndrome (KS)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controls matched for age, sex, and intelligence
Number of subjects: 3
Study: 10589865

Group type: EXPERIMENTAL
Intervention: 20 seconds rest interval (20 RI)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 60 seconds rest interval (60 RI)
Number of subjects: 7